148 reports of this reaction
1.5% of all ALBENDAZOLE reports
#14 most reported adverse reaction
COLITIS ULCERATIVE is the #14 most commonly reported adverse reaction for ALBENDAZOLE, manufactured by Amneal Pharmaceuticals LLC. There are 148 FDA adverse event reports linking ALBENDAZOLE to COLITIS ULCERATIVE. This represents approximately 1.5% of all 9,857 adverse event reports for this drug.
Patients taking ALBENDAZOLE who experience colitis ulcerative should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLITIS ULCERATIVE is a less commonly reported adverse event for ALBENDAZOLE, but still significant enough to appear in the safety profile.
In addition to colitis ulcerative, the following adverse reactions have been reported for ALBENDAZOLE:
The following drugs have also been linked to colitis ulcerative in FDA adverse event reports:
COLITIS ULCERATIVE has been reported as an adverse event in 148 FDA reports for ALBENDAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLITIS ULCERATIVE accounts for approximately 1.5% of all adverse event reports for ALBENDAZOLE, making it a notable side effect.
If you experience colitis ulcerative while taking ALBENDAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.